Fig. 5 | Nature Communications

Fig. 5

From: BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma

Fig. 5The alt text for this image may have been generated using AI.

SETD8-KD has a selective effect on LUSC cell line oncogenic capacity. a–c Comparison of colony numbers in 3D matrigel assay from control, shRNA1 or shRNA2 against SETD8 (a), SKIL (b) and TBX2 (c) in H520 cells. d Tumour kinetics of control or SETD8-KD H520 cells injected into immune compromised mice. Arrow indicates administration of doxycycline. e–g Comparison of colony numbers in 3D matrigel assay from control, shRNA1 or shRNA2 against SETD8 (e), SKIL (f) and TBX2 (g) in LK2 cells. Data presented as mean ± s.d. (n = 3). h Tumour kinetics of control or SETD8-KD LK2 cells injected into immune compromised mice. Arrow indicates administration of doxycycline. i–k Comparison of colony numbers in 3D matrigel assay from control, shRNA1 or shRNA2 against SETD8 (i), SKIL (j) and TBX2 (k) in H1792 cells. Data presented as mean ± s.d. (n = 3). l Tumour kinetics of control or SETD8-KD H1792 cells injected into immune compromised mice. Arrow indicates administration of doxycycline. Data presented as mean ± s.d. One-way ANOVA with post Dunnett test performed, *p < 0.05, **p < 0.005 and ***p < 0.001

Back to article page